Free Trial

Sera Prognostics (SERA) Competitors

Sera Prognostics logo
$2.50 +0.05 (+1.84%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$2.55 +0.05 (+2.20%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SERA vs. FLGT, CSTL, PSNL, INNV, EHAB, SBC, CELC, AUNA, TALK, and OMDA

Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), InnovAge (INNV), Enhabit (EHAB), SBC Medical Group (SBC), Celcuity (CELC), Auna (AUNA), Talkspace (TALK), and Omada Health (OMDA). These companies are all part of the "healthcare" industry.

Sera Prognostics vs. Its Competitors

Sera Prognostics (NASDAQ:SERA) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Sera Prognostics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.

Fulgent Genetics has a net margin of -13.94% compared to Sera Prognostics' net margin of -28,685.22%. Fulgent Genetics' return on equity of -2.19% beat Sera Prognostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sera Prognostics-28,685.22% -51.35% -37.21%
Fulgent Genetics -13.94%-2.19%-2.02%

Sera Prognostics has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sera Prognostics$80K1,174.83-$32.90M-$0.94-2.65
Fulgent Genetics$283.47M2.15-$42.71M-$1.33-15.08

In the previous week, Sera Prognostics and Sera Prognostics both had 2 articles in the media. Sera Prognostics' average media sentiment score of 0.72 beat Fulgent Genetics' score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sera Prognostics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fulgent Genetics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fulgent Genetics has a consensus target price of $24.00, suggesting a potential upside of 19.64%. Given Fulgent Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sera Prognostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Fulgent Genetics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 13.5% of Sera Prognostics shares are owned by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Fulgent Genetics beats Sera Prognostics on 9 of the 15 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SERA vs. The Competition

MetricSera PrognosticsMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$93.81M$7.31B$5.56B$9.03B
Dividend YieldN/A2.78%5.22%3.99%
P/E Ratio-2.6527.9427.6920.25
Price / Sales1,174.8332.30389.53161.89
Price / CashN/A22.0136.8958.10
Price / Book1.786.698.035.67
Net Income-$32.90M$233.06M$3.18B$249.21M
7 Day Performance-39.00%3.33%2.93%3.28%
1 Month Performance60.97%1.79%1.72%3.95%
1 Year Performance-53.71%37.40%34.39%20.98%

Sera Prognostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SERA
Sera Prognostics
1.3639 of 5 stars
$2.50
+1.8%
N/A-53.7%$93.81M$80K-2.65120
FLGT
Fulgent Genetics
2.9935 of 5 stars
$19.88
+1.0%
$24.00
+20.7%
+2.2%$599.13M$283.47M-14.951,313
CSTL
Castle Biosciences
3.0306 of 5 stars
$20.42
+0.3%
$37.00
+81.2%
+16.6%$587.55M$332.07M-107.47540
PSNL
Personalis
3.3805 of 5 stars
$6.56
-0.3%
$7.67
+16.9%
+393.8%$581.18M$85.69M-5.09400News Coverage
INNV
InnovAge
0.6383 of 5 stars
$3.69
-5.9%
$5.00
+35.5%
-13.1%$529.25M$763.85M-16.042,350News Coverage
EHAB
Enhabit
1.8814 of 5 stars
$9.64
+0.8%
$8.75
-9.2%
-10.9%$484.09M$1.03B-3.4810,700
SBC
SBC Medical Group
N/A$4.64
flat
N/AN/A$480.76M$205.42M0.00N/AHigh Trading Volume
CELC
Celcuity
2.1289 of 5 stars
$13.35
+6.5%
$30.80
+130.7%
-18.1%$474.84MN/A-4.4140Analyst Forecast
AUNA
Auna
3.5449 of 5 stars
$6.20
-2.2%
$10.70
+72.6%
-20.9%$469.24M$1.17B10.6914,842News Coverage
High Trading Volume
TALK
Talkspace
3.9167 of 5 stars
$2.78
+0.4%
$4.50
+61.9%
+29.6%$463.46M$187.59M139.07500Positive News
OMDA
Omada Health
N/A$18.30
+3.9%
N/AN/A$453.46MN/A0.00849News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SERA) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners